Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month High - Should You Buy?

Key Points

• Supernus Pharmaceuticals reached a new 52-week high of $49.66, with its last traded price at $48.49 and a trading volume of 939,438 shares.
• Analyst ratings show a mixed sentiment: Wall Street Zen downgraded the stock to "hold," while Cantor Fitzgerald increased the price target to $63, reflecting a generally favorable outlook.
• Insider activity revealed significant sales, with directors and executives selling over 300,000 shares combined over the last 90 days, raising potential concerns about ownership confidence.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) shares reached a new 52-week high on Monday . The company traded as high as $49.66 and last traded at $48.49, with a volume of 939438 shares trading hands. The stock had previously closed at $47.96.

Analyst Ratings Changes

A number of equities analysts have commented on SUPN shares. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday. Piper Sandler increased their price target on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a report on Friday, August 29th. Zacks Research upgraded Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 17th. Weiss Ratings reiterated a "hold (c)" rating on shares of Supernus Pharmaceuticals in a research note on Saturday, September 27th. Finally, Cantor Fitzgerald lifted their price target on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Supernus Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $51.50.

Supernus Pharmaceuticals Stock Performance

The firm has a 50 day simple moving average of $43.52 and a two-hundred day simple moving average of $36.17. The stock has a market cap of $2.72 billion, a P/E ratio of 42.20 and a beta of 0.78.

Insider Activity

In related news, Director Frederick M. Hudson sold 7,457 shares of the firm's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the transaction, the director owned 46,307 shares of the company's stock, valued at $1,956,933.82. This trade represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Frank Mottola sold 14,000 shares of the company's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $44.51, for a total transaction of $623,140.00. Following the completion of the sale, the senior vice president directly owned 15,496 shares of the company's stock, valued at $689,726.96. The trade was a 47.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 302,841 shares of company stock worth $13,361,449 in the last 90 days. 8.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Yousif Capital Management LLC lifted its position in shares of Supernus Pharmaceuticals by 1.5% during the 2nd quarter. Yousif Capital Management LLC now owns 21,032 shares of the specialty pharmaceutical company's stock valued at $663,000 after acquiring an additional 305 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Supernus Pharmaceuticals by 2.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,664 shares of the specialty pharmaceutical company's stock worth $480,000 after purchasing an additional 350 shares during the period. Maryland State Retirement & Pension System lifted its stake in Supernus Pharmaceuticals by 2.2% during the second quarter. Maryland State Retirement & Pension System now owns 16,455 shares of the specialty pharmaceutical company's stock valued at $519,000 after buying an additional 361 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Supernus Pharmaceuticals by 4.9% during the second quarter. Bank of Montreal Can now owns 10,144 shares of the specialty pharmaceutical company's stock valued at $320,000 after acquiring an additional 475 shares during the period. Finally, Vident Advisory LLC lifted its position in shares of Supernus Pharmaceuticals by 3.4% in the 1st quarter. Vident Advisory LLC now owns 14,886 shares of the specialty pharmaceutical company's stock valued at $488,000 after acquiring an additional 494 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.